文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

法布雷病心脏不良结局预测模型的开发与内部验证

Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry Disease.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

这项前瞻性纵向队列研究纳入200例连续接受心脏磁共振的法布雷病患者,中位随访4.5年,用Cox比例风险模型开发并内部验证了预测心脏不良复合结局的模型。最终简约模型含年龄、原生心肌T1离散度和指数化左心室质量,乐观校正后C统计量为0.77(95%CI:0.70-0.84),校准良好,并提供5年风险计算器。

要点

  • 年龄、原生心肌T1离散度、指数化左心室质量构成法布雷病心脏风险简约模型。
  • 模型内部验证C统计量0.77(95%CI:0.70-0.84),校准良好。
  • 模型可估算男女患者5年心脏不良结局风险,便于临床整合。

核心结论

  • 研究开发并内部验证了可准确预测法布雷病患者5年心脏不良结局风险的模型,尚需外部验证。

研究设计与样本

  • 前瞻性纵向队列研究,纳入200例连续接受心脏磁共振的法布雷病患者,中位随访4.5年(IQR:2.7-6.3年),采用Cox比例风险模型开发并内部验证预后模型。

主要发现

  • 表现最佳的简约多变量模型纳入年龄、原生心肌T1离散度(每体素心肌T1弛豫时间的标准差)和指数化左心室质量。
  • 在5个插补模型开发数据集上,乐观校正后C统计量中位数为0.77(95%CI:0.70-0.84)。
  • 模型在全风险谱内校准优秀。

关键数值与推荐

  • 风险计算器可提供包括男性和女性在内的个体患者5年心脏不良结局估计风险。

临床怎么用

  • 该模型可较容易地整合到临床诊疗中,用于法布雷病患者的个体化风险分层与治疗决策参考。

局限性

  • 研究仅为内部验证,外部验证尚未进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cardiac manifestations of Fabry disease are the leading cause of death, but risk stratification remains inadequate. Identifying patients who are at risk of adverse cardiac outcome may facilitate more evidence-based treatment guidance. Contemporary cardiovascular cardiac magnetic resonance biomarkers have become widely adopted, but their prognostic value remains unclear. OBJECTIVES: The objective of this study was to develop, internally validate, and evaluate the performance of, a prognostic model, including contemporary deep phenotyping, which can be used to generate individual risk estimates for adverse cardiac outcome in patients with Fabry disease. METHODS: This longitudinal prospective cohort study consisted of 200 consecutive patients with Fabry disease undergoing clinical cardiac magnetic resonance. Median follow-up was 4.5 years (IQR: 2.7-6.3 years). Prognostic models were developed using Cox proportional hazards modeling. Outcome was a composite of adverse cardiac events. Model performance was evaluated. A risk calculator, which provides 5-year estimated risk of adverse cardiac outcome for individual patients, including men and women, was generated. RESULTS: The highest performing, internally validated, parsimonious multivariable model included age, native myocardial T1 dispersion (SD of per voxel myocardial T1 relaxation times), and indexed left ventricular mass. Median optimism-adjusted c-statistic across 5 imputed model development data sets was 0.77 (95% CI: 0.70-0.84). Model calibration was excellent across the full risk profile. CONCLUSIONS: This study developed and internally validated a risk prediction model that accurately predicts 5-year risk of adverse cardiac outcome for individual patients with Fabry disease, including men and women, which could easily be integrated into clinical care. External validation is warranted.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Orsborne C, Bradley J, Bonnett LJ, et al. Validated Model for Prediction of Adverse Cardiac Outcome in Patients With Fabry Disease. J Am Coll Cardiol. 2022. PMID: 36049806. doi:10.1016/j.jacc.2022.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。